Nucleai
Signal active
Organization
Contact Information
Overview
Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies, licensing its research platform for internal use, and collaborating in biomarkers discovery projects.
About
Industries
Artificial Intelligence (AI), Machine Learning, Health Care
Founded
2017
Employees
51-100
Headquarters locations
Asia
Social
N/A
Profile Resume
Nucleai headquartered in Asia, operates in the Artificial Intelligence (AI), Machine Learning, Health Care sector. The company focuses on Artificial Intelligence (AI) and has secured $2.9B in funding across 48 round(s). With a team of 51-100 employees, Nucleai is actively contributing to advancements in Artificial Intelligence (AI). Their latest funding round, Venture Round - Nucleai, raised $14.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
3
Lead Investors
0
Total Funding Amount
$60.5M
Details
3
Nucleai has raised a total of $60.5M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2018 | Seed | 5.0M | ||
| 2020 | Early Stage Venture | 8.5M | ||
| 2022 | Early Stage Venture | 33.0M |
Investors
Nucleai is funded by 32 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| M Ventures | - | FUNDING ROUND - M Ventures | 14.0M |
| Grove Ventures | - | FUNDING ROUND - Grove Ventures | 14.0M |
| Nucleai | - | FUNDING ROUND - Nucleai | 14.0M |
| Merck KGaA, Darmstadt, Germany | - | FUNDING ROUND - Merck KGaA, Darmstadt, Germany | 14.0M |
Recent Activity
There is no recent news or activity for this profile.